<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119569</url>
  </required_header>
  <id_info>
    <org_study_id>GN43271</org_study_id>
    <secondary_id>2021-003772-14</secondary_id>
    <nct_id>NCT05119569</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)</brief_title>
  <acronym>FENopta</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study evaluating the effect of fenebrutinib on brain MRI in participants with RMS.&#xD;
      The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be&#xD;
      randomized to receive either fenebrutinib or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">September 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will also be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of new gadolinium-enhancing T1 lesions observed on MRI scans of the brain</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new or enlarging T2-weighted lesions observed on MRI scans of the brain</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants free from any new gadolinium-enhancing T1 lesions and new or enlarging T2-weighted lesions observed on MRI scans of the brain</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of fenebrutinib at specified timepoints</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>fenebrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral fenebrutinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive oral placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenebrutinib</intervention_name>
    <description>fenebrutinib will be administered orally.</description>
    <arm_group_label>fenebrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo will be administered orally.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria.&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse) or use contraceptive measures, and refrain&#xD;
             from donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease duration of &gt; 10 years from the onset of symptoms and an EDSS score at&#xD;
             screening &lt; 2.0.&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding, or intending to become&#xD;
             pregnant.&#xD;
&#xD;
          -  Male participants who intend to father a child during the study.&#xD;
&#xD;
          -  A diagnosis of Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary&#xD;
             Progressive Multiple Sclerosis (SPMS).&#xD;
&#xD;
          -  Any known or suspected active infection at screening, including but not limited to a&#xD;
             positive screening tests for Hepatitis B and C, an active or latent or inadequately&#xD;
             treated infection with tuberculosis (TB), a confirmed or suspected progressive&#xD;
             multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          -  History of cancer including hematologic malignancy and solid tumors within 10 years of&#xD;
             screening.&#xD;
&#xD;
          -  Known presence of other neurological disorders, clinically significant cardiovascular,&#xD;
             psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal&#xD;
             disease.&#xD;
&#xD;
          -  Any concomitant disease that may require chronic treatment with systemic&#xD;
             corticosteroids or immunosuppressants during the course of the study.&#xD;
&#xD;
          -  History of alcohol or other drug abuse within 12 months prior to screening.&#xD;
&#xD;
          -  History of or currently active primary or secondary (non-drug-related)&#xD;
             immunodeficiency, including known history of HIV infection.&#xD;
&#xD;
          -  Inability to complete an MRI scan.&#xD;
&#xD;
          -  Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Receipt of a live-attenuated vaccine within 6 weeks prior to randomization.&#xD;
&#xD;
          -  Any previous treatment with immunomodulatory or immunosuppressive medication without&#xD;
             an appropriate washout period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN43271 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

